Jeevan Scientific Peer Comparison

BSE: 538837

₹73.15

₹-0.99 (-1.34%)

As on 28-Aug-2026IST

Market cap

₹147 Cr

Revenue (TTM)

₹71 Cr

P/E Ratio

42.1

P/B Ratio

2

Div. Yield

0 %

Edit

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Market cap (₹ Cr)	147	2,760	180	50,741	39,538
Revenue (₹ Cr)	71	419	--	2,002	4,683
Net Profit (₹ Cr)	5.14	79.66	-0.86	575.95	552.34
Net Margin (%)	7.16	18.53	-2,391.67	26.66	11.55
RoE (%)	5.85	18.52	-3.56	20.48	14.93
Price to Earnings	42.12	34.65	--	88.10	71.09
Price-To-Book	2.01	5.87	4.52	16.21	9.62

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Operating Revenue	71.02	418.80	0.00	2,002.34	4,683.37
Total Income	71.83	429.85	0.04	2,160.20	4,783.78
Total Expenditure	56.46	273.66	0.87	1,209.46	3,704.62
EBITDA	14.55	145.14	-0.87	792.89	978.75
Depreciation	6.61	46.46	0.02	137.61	246.41
EBIT	7.95	98.68	-0.90	655.28	732.34
Interest	1.94	1.09	0.00	6.17	92.01
Other Income	0.81	11.05	0.04	157.86	100.41
Exceptional Items	0.00	-1.62	0.00	-24.39	-20.61
Profit before Tax	6.82	107.03	-0.86	782.58	720.14
Provision for Tax	1.68	27.37	0.00	206.63	167.80
Profit after Tax	5.14	79.66	-0.86	575.95	552.34

Liabilities (₹ Cr)

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Shareholder's Funds	71.94	456.87	40.07	3,042.52	3,961.57
Minority Interest	-1.63	0.00	0.00	0.00	3.84
Non-Current Liabilities	13.74	39.83	0.00	61.06	1,293.60
Current Liabilities	19.89	65.52	5.24	325.71	627.13
Total Liabilities	78.29	466.53	8.84	2,966.58	4,766.23

Assets (₹ Cr)

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Non-Current Assets	40.19	329.41	0.00	1,421.55	3,128.95
Current Assets	49.87	224.87	45.31	1,803.15	1,674.92
Total Assets	78.29	466.53	8.84	2,966.58	4,766.23
Total Debt*	15.14	8.52	0.00	108.96	327.88
Net Current Assets	29.98	159.35	40.07	1,477.43	1,047.79
Contingent Liabilities	--	2.74	--	54.44	88.77

Cashflow (₹ Cr)

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Cash From Operating Activities	10.07	94.05	0.00	270.55	623.76
Cash Flow from Investing Activities	-15.62	-75.54	--	-146.56	-720.94
Cash from Financing Activities	5.24	-16.12	--	-135.65	-97.23
Net Cash Inflow / Outflow	-0.30	2.40	0.00	-11.66	-194.41

Ratios

Profitability Ratios

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
ROCE (%)	3.17	25.23	51.69	28.55	20.50
ROE (%)	5.85	18.52	-3.56	20.48	14.93
ROA (%)	5.56	15.49	-3.18	33.59	10.35
EBIT Margin (%)	11.19	23.56	--	32.73	15.64
Net Margin (%)	7.16	18.53	-2,391.67	26.66	11.55
Cash Profit Margin (%)	0.00	0.00	--	0.00	0.00

Growth Ratios

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Revenue Growth (%)	61.33	14.22	--	-2.14	21.27
EBIT Growth (%)	393.61	6.64	-382.26	1.71	0.94
Net Profit Growth (%)	330.83	11.04	-124.73	14.12	3.43
EPS Growth (%)	235.44	-35.38	-119.33	17.10	2.70
Book Value Growth (%)	1.09	21.06	69.71	23.43	16.71

Valuation Ratios

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Price / Earnings	38.03	34.08	-76.80	85.31	69.04
Price / Book Value	2.01	5.87	4.52	16.21	9.62
Dividend Yield (%)	0.00	0.32	0.00	0.22	0.03
EV/EBITDA	11.12	18.58	-205.79	62.87	39.89
Market Cap (₹ Cr)	63.50	2,223.71	--	0.00	32,181.74

Solvency Ratios

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Debt to Equity	0.14	0.00	0.00	0.01	0.15
Short term debt to equity ratio	0.02	--	--	0.02	--
Current Ratio	2.51	3.43	8.64	5.54	2.67
Quick Ratio	2.35	2.97	8.64	5.15	2.54
Interest Coverage	4.51	99.28	--	127.84	8.83

Operating Efficiency Ratios

	Jeevan Scientific	Vimta Labs	Genesis IBRC India	Anthem Biosciences	Global Health
Debtors to sales (%)	29.14	25.24	--	29.49	8.78
Asset Turnover	0.77	0.81	0.00	1.17	0.88
Receivable days	110.00	102.52	--	92.78	25.07
Inventory Days	10.55	26.39	--	54.41	6.62
Payable days	255.53	--	--	51.72	79.17
Cash Conversion Cycle	-134.98	--	--	95.47	-47.48

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.